報價延遲最少15分鐘:2025/01/21 05:38 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
18.09 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.33/0.64
|
|
企業價值
878.82M
|
| 資產負債 |
|
每股賬面淨值
2.26
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
159.01M
|
|
每股收益
3.46
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/01/21 05:38 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically, economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries. |